EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische StudieOpen Access · CC BY 4.0

Sirolimus treatment for intractable vascular anomalies ( SIVA ): An open‐label, single‐arm, multicenter, prospective trial

Michio Ozeki iD, Saori Endo, Shiho Yasue, Ryuta Asada, Akiko M Saito, Hiroya Hashimoto, Shigeru Ueno, Shoji Watanabe, Motoi Kato, Kyoichi Deie, Shunsuke Nosaka, Mikiko Miyasaka und 12 weitere

Pediatrics International · 2025-01 · 67 (1)

DOI: 10.1111/ped.70002 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Pediatrics International, online erschienen am 26.03.2025. Verfasst von Michio Ozeki und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Graduate School of Medicine, Gifu University, Gifu, Japan. Hauptthemen laut MEDLINE: Sirolimus, Vascular Malformations. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Intractable vascular anomalies (VAs), including vascular tumors and venous, lymphatic, and mixed malformations, often have severe symptoms and a poor prognosis, highlighting the need for new treatments. We conducted a prospective trial of sirolimus (tablet and granule forms) for the treatment of VAs.

Methods

In this open‐label, single‐arm, multicenter trial across four Japanese institutions, patients with VAs received oral sirolimus daily, targeting a trough concentration of 5–15 ng/mL. We evaluated response rates (radiological volume changes in lesions), skin lesions, performance status, respiratory function, visceral symptoms (bleeding, pain), laboratory data, quality of life, and safety at 12, 24, and 52 weeks.

Results

Thirteen patients with VAs were treated with sirolimus. Seven patients (53.8%; 95% confidence interval: 25.1%–80.8%) showed a partial radiological response at 24 weeks, with no complete responses, and 61.5% had a partial response by 12 weeks, with little subsequent change in patients who had stable disease thereafter. Improvements in skin lesions, blood coagulation, and activities of daily living were noted. Common adverse events included stomatitis, dermatitis, diarrhea, and fever.

Conclusions

Sirolimus may reduce VA tissue volume and potentially improve symptoms and activities of daily living in patients with VAs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SirolimusVascular MalformationsHumansMaleFemaleProspective StudiesChild, PreschoolChildTreatment OutcomeInfantAdolescentAdministration, OralQuality of Life

Stichwörter der Autor:innen

mammalian target of rapamycinsirolimus granulevascular malformationsvascular tumorsvenous malformations

Substanzen

Sirolimus

Autor:innen und Institutionen

  • Department of Pediatrics, Graduate School of Medicine, Gifu University, Gifu, Japan.
  • Clinical Research Center, NHO Nagoya Medical Center, Nagoya, Japan.
  • Innovative and Clinical Research Promotion Center, Graduate School of Medicine, Gifu University, Gifu, Japan.
  • Core Laboratory, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
  • Department of Pediatric Surgery, Tokai University School of Medicine, Hiratsuka, Japan.
  • Department of Plastic Surgery, Saitama Children's Medical Center, Saitama, Japan.

ORCID-Profile: Michio Ozeki, Takanobu Maekawa, Shigehisa Fumino, Naonori Kawakubo, Akihiro Fujino

Förderung

  • Japan Agency for Medical Research and Development

Zitieren

APA

Ozeki, M., Endo, S., Yasue, S., Asada, R., Saito, A. M., Hashimoto, H., Ueno, S., Watanabe, S., Kato, M., Deie, K., Nosaka, S., Miyasaka, M., Umezawa, A., Matsuoka, K., Kato, M., Kuroda, T., Maekawa, T., Hirakawa, S., Furukawa, T., …, & Fujino, A. (2025). Sirolimus treatment for intractable vascular anomalies ( SIVA ): An open‐label, single‐arm, multicenter, prospective trial. Pediatrics International, 67(1). https://doi.org/10.1111/ped.70002

Vancouver

Ozeki M, Endo S, Yasue S, Asada R, Saito AM, Hashimoto H, et al. Sirolimus treatment for intractable vascular anomalies ( SIVA ): An open‐label, single‐arm, multicenter, prospective trial. Pediatrics International. 2025;67(1). doi:10.1111/ped.70002

BibTeX
@article{Ozeki2025,
  author = {Ozeki, Michio and Endo, Saori and Yasue, Shiho and Asada, Ryuta and Saito, Akiko M and Hashimoto, Hiroya and Ueno, Shigeru and Watanabe, Shoji and Kato, Motoi and Deie, Kyoichi and Nosaka, Shunsuke and Miyasaka, Mikiko and Umezawa, Akihiro and Matsuoka, Kentaro and Kato, Mototoshi and Kuroda, Tatsuo and Maekawa, Takanobu and Hirakawa, Satoshi and Furukawa, Taizo and Fumino, Shigehisa and Tajiri, Tatsuro and Takemoto, Junkichi and Kawakubo, Naonori and Fujino, Akihiro},
  title = {Sirolimus treatment for intractable vascular anomalies ( SIVA ): An open‐label, single‐arm, multicenter, prospective trial},
  journal = {Pediatrics International},
  year = {2025},
  volume = {67},
  number = {1},
  doi = {10.1111/ped.70002}
}
Kostenlos starten →